Tesamorelin vs Ipamorelin
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone that stimulates endogenous, pulsatile growth hormone secretion at the GHRH receptor, and it was approved for HIV-associated lipodystrophy on the strength of multicentre phase 3 trials with visceral adipose tissue as the primary endpoint. Ipamorelin is a synthetic pentapeptide acting at a different receptor entirely, growth hormone secretagogue receptor 1a, the ghrelin receptor, and it holds no marketing authorisation anywhere; its largest trial, a randomised placebo-controlled phase 2 study in postoperative ileus, did not separate from placebo. The two are habitually paired because both raise growth hormone through the pituitary rather than replacing it. No published study has administered both, in humans or in animals. The nine publications that engage both are narrative and scoping reviews of injectable peptides published in 2026, one review of peptide pharmacokinetics, and the two most recent annual anti-doping literature surveys, which catalogue them within the same prohibited class.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No experiment has administered tesamorelin and ipamorelin to the same subjects, in parallel arms or in combination, and no animal study has done so either. Searches of PubMed and Europe PMC returned nine publications that engage both, and every one of them is secondary literature. Six are narrative or scoping reviews published in 2026 that survey injectable peptides in sports medicine, orthopaedics and endocrinology; they place tesamorelin among approved or clinically evaluated agents and ipamorelin among unapproved growth hormone secretagogues, and none reports comparative data. A 2021 review of peptide pharmacokinetics used the two as worked examples of different stabilisation chemistries, ipamorelin for substitution with unnatural amino acids and tesamorelin for modification at the peptide terminus. The two most recent annual banned-substance reviews list both within the World Anti-Doping Agency classification of growth hormone releasing factors and secretagogues, which is a cataloguing exercise rather than a comparison. Any comparison between the two is therefore indirect, assembled from separate trials that used different populations, endpoints and durations.
The 9 publications that cover both
- 01Review2026
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Dominikowski A, et al. · Frontiers in Endocrinology · narrative review of peptides acting on the GH-IGF-1 axis; both compounds discussed, neither administered
The review surveyed peptides marketed for performance enhancement that act on the GH-IGF-1 axis, separating GHRH analogues such as tesamorelin from growth hormone secretagogues such as ipamorelin, and proposed a clinical assessment algorithm for patients self-administering them. The authors reported that clinically meaningful benefit in healthy individuals remained uncertain because the human evidence base was limited and largely indirect.
- 02Review2026
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications
Villegas Meza AD, et al. · JBJS Reviews · structured narrative review of injectable peptides published between 2020 and 2025; both compounds named, neither administered
The review classified injectable peptides into five functional classes and found that only glucagon-like peptide-1 agonists carried reproducible randomised evidence for a musculoskeletal indication. The growth hormone axis agents, covering both the GHRH analogue and the secretagogue classes to which these two compounds belong, were categorised as experimental, and use was recommended to be confined to approved agents and formal research protocols.
- 03Review2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Mendias CL, Awan TM · Sports Medicine · narrative review contrasting approved and unapproved peptide therapies; both compounds named, neither administered
The review separated regulator-approved peptide drugs from a parallel market of unapproved compounds used in sports medicine and covered mechanisms, safety and regulatory status for each group. The authors reported that although animal models suggested activity for several agents, rigorous human safety data remained scarce for most unapproved peptides.
- 04Review2026
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield CK, et al. · The American Journal of Sports Medicine · primer-style review of commonly encountered injectable peptides; both compounds named, neither administered
The primer described the injectable peptides most often encountered in orthopaedic and sports medicine practice, including GHRH analogues and growth hormone secretagogues. It reported that human orthopaedic outcome data remained largely absent despite preclinical signals, and concluded that further safety and efficacy research was required before definitive recommendations could be made.
- 05Review2026
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF, Lee SJ, Seeds WA · JAAOS Global Research & Reviews · narrative review of therapeutic peptides in orthopaedics; both compounds grouped as growth hormone secretagogues, neither administered
The review grouped ipamorelin, CJC-1295, tesamorelin, sermorelin and AOD-9604 together as growth hormone secretagogues described as acting through IGF-1 signalling and satellite cell repair, and set that group alongside wound-healing, recovery and neuroactive peptide classes. It presented the class as an emerging adjunct rather than an established treatment and made no comparison between individual members.
- 06Review2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Renke G, Chinellato L · International Journal of Molecular Sciences · literature review of 106 articles on therapeutic peptides; both compounds named, neither administered
The review distinguished GHRH analogues, listing tesamorelin as a high-potency analogue approved for HIV-associated lipodystrophy because it reduces visceral fat, from growth hormone-releasing peptides acting at the ghrelin receptor, among which ipamorelin was listed. The authors concluded that further study was required before most newer peptides could be considered safe for human use.
- 07Review2021
Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Peptides: When Is the Assessment of Certain Factors Warranted?
Mahmood I, Pettinato M · Antibodies · review of intrinsic and extrinsic factors affecting peptide pharmacokinetics; both compounds cited as chemistry examples
The review used the two compounds to illustrate different strategies for slowing peptide degradation. Ipamorelin was cited as an example of substitution with unnatural or D-amino acids, and tesamorelin as an example of chemical modification at the peptide terminus, described as a hexenoyl moiety attached to the N-terminal tyrosine residue. No pharmacokinetic comparison between the two was presented.
- 08Review2026
Annual Banned-Substance Review 18th Edition-Analytical Approaches in Human Sports Drug Testing 2024/2025
Thevis M, Kuuranne T, Geyer H · Drug Testing and Analysis · annual survey of analytical approaches in human sports drug testing, covering literature published between October 2024 and September 2025
The review organised the doping-control literature by the World Anti-Doping Agency peptide hormone classification and listed both compounds within it, tesamorelin among GHRH analogues and ipamorelin among growth hormone secretagogues, before surveying the detection methods published for those classes during the review period. Its subject was analytical detection rather than pharmacological effect.
- 09Review2025
Annual Banned-Substance Review 17th Edition-Analytical Approaches in Human Sports Drug Testing 2023/2024
Thevis M, Kuuranne T, Geyer H · Drug Testing and Analysis · annual survey of analytical approaches in human sports drug testing, covering literature published between October 2023 and September 2024
The review catalogued both compounds within the prohibited peptide hormone classes it uses to organise the field, tesamorelin among GHRH analogues and ipamorelin among growth hormone secretagogues, and reported that growth hormone releasing factors and secretagogues continued to attract analytical attention alongside preclinical and clinical study. No pharmacological comparison between the compounds was made.
Side by side.
| Tesamorelin | Ipamorelin | |
|---|---|---|
| Evidence maturity | Approved drug | Early clinical |
| Studies cited here | 15 | 15 |
| Published 2023 or later | 11 | 9 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | A synthetic analogue of human growth hormone-releasing hormone, built on the endogenous releasing hormone sequence and carrying a modification at the N-terminal tyrosine that slows enzymatic degradation. | A synthetic pentapeptide with no endogenous counterpart, identified in a chemistry programme that removed the central dipeptide of GHRP-1 and characterised in 1998. |
| Receptor engaged | The GHRH receptor on the anterior pituitary, the same receptor the endogenous releasing hormone uses, with output still shaped by hypothalamic somatostatin rhythm. | Growth hormone secretagogue receptor 1a, the ghrelin receptor, a separate site within the same axis. The original characterisation reported growth hormone release without ACTH or cortisol elevation above the levels seen after GHRH stimulation. |
| Size and design of the human evidence | Multicentre randomised placebo-controlled trials, including a 412-participant trial in people with HIV and abdominal fat accumulation, later randomised trials in hepatic fat and neurocognition, and 2026 meta-analyses pooling four and five randomised trials. | Two published human datasets: a 1999 dose-escalation pharmacokinetic-pharmacodynamic study in healthy volunteers, and a randomised placebo-controlled phase 2 trial in 114 bowel resection patients. |
| Best-characterised finding | Reduction of visceral adipose tissue. In the pivotal 26-week trial visceral adipose tissue decreased by 15.2% with tesamorelin and increased by 5.0% with placebo, and a later 12-month trial reported an absolute hepatic fat fraction effect of -4.1%. | Selective growth hormone release. Preclinical work reported dose-dependent longitudinal bone growth and body weight gain in rats over 15 days, without significant change in circulating IGF-I or in markers of bone formation and resorption. |
| What the largest trial concluded | The pivotal trials met their visceral adipose tissue endpoint and the compound was approved on that basis, while the largest recent neurocognitive trial in people with HIV found no significant between-group difference. | The phase 2 postoperative ileus trial reported that ipamorelin was well tolerated but produced no statistically significant difference from placebo in time to first tolerated meal, and development for that indication did not proceed. |
| Regulatory status | Approved for HIV-associated lipodystrophy and classified in this library as an approved drug, while also prohibited in sport as a growth hormone releasing factor. | No marketing authorisation in any jurisdiction for any indication. It is listed among prohibited growth hormone secretagogues and described across the 2026 reviews as an unapproved research compound. |
| Recency and direction of primary research | Active and clinical. Output from 2024 to 2026 includes a randomised trial in people with HIV on integrase inhibitors, two meta-analyses of the lipodystrophy trials, a published protocol for an exercise-adjunct trial, and preclinical GHRH-agonist neurobiology. | Largely dormant as primary research. Recent publications are a ferret model of cisplatin-induced weight loss, a cichlid fish reproductive-axis study, and narrative reviews rather than new human data. |
| Basis of most marketing claims | Extrapolation from HIV-associated lipodystrophy trials, where the population, endpoint and comparator were narrowly defined, to general fat loss in people without that condition. | Extrapolation from the 1998 selectivity characterisation and rodent growth data to human body composition, sleep and recovery outcomes that no published trial has measured. |
And what it does not.
Nothing in the published record establishes how these two compounds compare, because no experiment has run them side by side. The separate literatures are asymmetric rather than contradictory. Tesamorelin has multicentre randomised placebo-controlled trials with imaging endpoints, a regulatory approval built on them, meta-analyses of those trials and continuing clinical research; it also has clear limits, since the controlled evidence sits almost entirely within HIV-associated lipodystrophy and hepatic steatosis, and the largest recent neurocognitive trial found no significant between-group difference. Ipamorelin has a 1998 selectivity characterisation, rodent and ferret work, one human pharmacokinetic modelling study and one randomised trial that did not separate from placebo, with no marketing authorisation anywhere. Neither compound has controlled human evidence for the outcomes that prompt the comparison in the first place, which are lean mass, recovery, sleep and general body composition in healthy adults. The receptor difference between them is real and well described, but it has never been translated into a measured difference on any shared endpoint.
Common questions.
- Has any experiment given tesamorelin and ipamorelin to the same subjects?
No. Searches of PubMed and Europe PMC located no study, in humans or in animals, that administered both compounds, whether as parallel arms, a crossover or a combination. The publications that engage both are secondary literature: narrative and scoping reviews of injectable peptides published in 2026, a review of peptide pharmacokinetics that used them as chemistry examples, and annual anti-doping literature surveys that group them within the same prohibited class. None of those generates comparative pharmacodynamic data, so every stated difference between the two rests on separate studies.
- Which of the two has been through a phase 3 programme?
Tesamorelin. It was evaluated in multicentre randomised placebo-controlled trials in people with HIV and excess abdominal fat, with visceral adipose tissue as the primary endpoint, and was approved for HIV-associated lipodystrophy on that basis. Ipamorelin never entered phase 3. Its clinical development reached a prospective, randomised, placebo-controlled phase 2 proof-of-concept trial in 114 bowel resection patients with postoperative ileus, which did not meet its primary endpoint, and development for that indication did not continue.
- What did the largest published ipamorelin trial measure?
Time to first tolerated meal after bowel resection. The Ipamorelin 201 Study Group ran a prospective, randomised, placebo-controlled phase 2 proof-of-concept study in 114 patients recovering from bowel resection, testing the compound for management of postoperative ileus. Ipamorelin was reported as well tolerated but did not produce a statistically significant difference from placebo on that endpoint. No randomised controlled trial has since demonstrated a clinical benefit of ipamorelin on any efficacy endpoint, and none has measured body composition or recovery in healthy adults.
- Why do the 2026 reviews list both compounds without comparing them?
Because their purpose is classification rather than measurement. The 2026 reviews in sports medicine, orthopaedics and endocrinology were written to map an unregulated market for clinicians, so they group compounds by mechanism, record what is approved and what is not, and summarise the state of the evidence for each group. Several state plainly that human outcome data are largely absent for the unapproved agents they cover. Producing comparative data would require an experiment that administered both, and none has been published.
- Does either compound have published data on lean mass or recovery in healthy adults?
Neither has controlled data in healthy adults. Tesamorelin trials reported an increase in lean body mass, but in people with HIV-associated lipodystrophy rather than in healthy volunteers, and a protocol for a trial combining it with exercise in older adults with HIV has been published without results. The relevant ipamorelin record is rodent longitudinal bone growth and body weight gain plus one human pharmacokinetic modelling study. Effects on body composition, musculoskeletal recovery and sleep in non-clinical populations remain unstudied for both.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.